Cassava Sciences Inc vs Global E Online Ltd — how do they compare? Cassava Sciences Inc trades at $0.97 (market cap $47.75M), while Global E Online Ltd trades at $40.82 (market cap $6.90B). The key difference: Global E Online Ltd is far larger — about 144.5× Cassava Sciences Inc's market cap, and Global E Online Ltd is trading nearer its 52-week high, Cassava Sciences Inc nearer its low. Which is the better fit depends on your goals.
| FLNA | GLBE | |
|---|---|---|
Market Cap | $47.75M | $6.90B |
Sector | Health | Technology |
52-Week High | $4.64 | $42.32 |
52-Week Low | $0.87 | $27.54 |
Enterprise Value | -$34.93M | $6.37B |
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $0.995, up 3.75% today, with a bearish technical signal from moving averages but neutral oscillators. The company reported three consecutive quarterly earnings beats, with Q2 2026 EPS of -$0.18 beating expectations of -$0.225. Financials show negative cash flows and profitability, with ROE at -55.79% and net income of -$90.97M in 2025. Analyst consensus is strongly positive with 8 buy ratings out of 12.
Despite operational losses, FLNA's consistent earnings beats and strong analyst support suggest potential upside if clinical developments progress. Key risks include sustained cash burn, lack of revenue, and dependence on successful drug trials for Tuberous Sclerosis Complex. The stock remains speculative with high volatility expected.
GLBE trades at $42.32, up 3.17% in the past 24 hours, near its 52-week high. The stock shows bullish technical signals with strong moving average support, though RSI indicates overbought conditions. Recent earnings have been mixed, with a beat in Q4 2025 but a miss in Q1 2026. The company reported 2025 revenue of $962.20 million and net income of $68.27 million, with profitability improving into 2026. Key developments include the acquisition of Passport to enhance logistics capabilities and a $500 million share repurchase program authorized by the board.
GLBE presents a growth opportunity with robust analyst support—100% buy ratings and a consensus price target of $44.75, suggesting upside potential. However, risks include high valuation multiples like a P/E of 61.33, competitive pressures in e-commerce enablement, and insider selling by the CEO. Investors should weigh the strong growth trajectory against premium valuation and market volatility.
Trailing returns across standard periods
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →Global-e provides a platform for cross-border e-commerce, helping retailers increase international sales by localizing the shopping experience for consumers in over 200 destinations worldwide.
Read more on GLBE →